Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 80% Improvement Relative Risk c19hcq.org Huang et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 1,255 patients in China Lower hospitalization with HCQ (p=0.001) Huang et al., Annals of the Rheumatic Diseases 2.., doi:10.1136/annrheumdis-2020-217425 Favors HCQ Favors control

Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study

Huang et al., Annals of the Rheumatic Diseases 2020:79, 1163-1169, doi:10.1136/annrheumdis-2020-217425
Huang et al., Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study, Annals of the Rheumatic Diseases 2020:79, 1163-1169, doi:10.1136/annrheumdis-2020-217425
Jun 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Analysis of 1255 COVID-19 patients in Wuhan Tongji Hospital finding 0.61% with systemic autoimmune diseases, much lower than authors expected (3%-10%). Authors hypothesise that protective factors, such as CQ/HCQ use, reduce hospitalization. This study is excluded in the after exclusion results of meta analysis: significant unadjusted confounding possible.
risk of hospitalization, 80.0% lower, RR 0.20, p < 0.001, treatment 8, control 1,247.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Huang et al., 16 Jun 2020, retrospective, China, peer-reviewed, 15 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study
Yao Huang, Zhe Chen, Yu Wang, Liang Han, Kai Qin, Wenya Huang, Ying Huang, Hui Wang, Pan Shen, Xin Ba, Weiji Lin, Hui Dong, Mingmin Zhang, Professor Shenghao Tu
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217425
What is already known about this subject? ► On 12 March, WHO declared COVID-19 could be characterised as a pandemic. Till 22 April, more than 2.5 million cases of COVID-19 have been reported worldwide. ► Increasing data about COVID-19 based on the general population has been reported. However, little published works were found about COVID-19 in disease-specific groups. What does this study add? ► We analysed the epidemiology of 1255 inpatients with COVID-19 who were admitted to Wuhan Tongji Hospital. Additional 17 patients with systemic autoimmune diseases (AIDs) were further screened, the demographic characteristics, epidemiological history, comorbidities, clinical symptoms or signs on admission, chest CT findings, laboratory results on admission, therapies that were prescribed for COVID-19 as well as AIDs, and clinical outcomes were reported. The detailed information of patients with systemic AIDs was investigated.
Competing interests none declared. Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research. Patient consent for publication not required. Ethics approval This study was approved by the ethics Commission of Tongji Hospital, Tongji Medical College, Huazhong University of science and Technology (TJ-iRB20200365). Written informed consent was waived by Tongji Hospital for emerging infectious diseases and the urgent need to collect data. Provenance and peer review not commissioned; externally peer reviewed. data availability statement Data are available upon reasonable request by email to shtu@ tjh. tjmu. edu. cn. This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, on January 16, 2022 by guest. Protected by copyright. http://ard.bmj.com/
References
Chen N, Zhou, Dong, epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, doi:10.1016/S0140-6736(20)30211-7
Clinicaltrials, Gov, Post-exposure prophylaxis / preemptive therapy for saRs-Coronavirus-2-full text view
Gautret, Parola, Hydroxychloroquine and azithromycin as a treatment of COViD-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Guan, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Hari, Gs, Levy Ml, Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3), Nephron Clin Pract, doi:10.1001/jama.2016.0289
Hemminki, Huang, autoimmune diseases and hematological malignancies: exploring the underlying mechanisms from epidemiological evidence, Semin Cancer Biol, doi:10.1016/j.semcancer.2019.06.005
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Jaillon S, Berthenet, Garlanda, sexual dimorphism in innate immunity, Clin Rev Allergy Immunol, doi:10.1007/s12016-017-8648-x
Kim Ahj, Sparks, Liew, a rush to judgment? rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COViD-19, Ann Intern Med, doi:10.7326/M20-1223
Li, Guan, Wu, early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med, doi:10.1056/NEJMoa2001316
Lu, Zhao, Li, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, doi:10.1016/S0140-6736(20)30251-8
Roberts, Comparative United states autoimmune disease rates for 2010-2016 by sex, geographic region, and race, Autoimmun Rev, doi:10.1016/j.autrev.2019.102423
Smolen Js, Bijlsma, eUlaR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, Ann Rheum Dis, doi:10.1136/annrheumdis-2019-216655
Subramanian Vs, Ga, Tumor necrosis factor alpha reduces intestinal vitamin C uptake: a role for nF-κB-mediated signaling, Am J Physiol Gastrointest Liver Physiol, doi:10.1152/ajpgi.00071.2018
Wang, Me, Human autoimmune diseases: a comprehensive update, J Intern Med, doi:10.1111/joim.12395
Yao, Ye, Zhang, in vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (saRs-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COViD-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Zhu N, Zhang, Wang, a novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit